Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (June 2026)
15 slides from Netramark's investor presentation, June 2026
Slide 1: Precision AI That Identifies Patients Driving Clinical Trial Success & Failure
NETRAMARK HOLDINGS INC. Precision AI That Identifies Patients Driving Clinical Trial Success & Failure FDA-reviewed | Peer-reviewed (Nature portfolio) | Commercially deployed | CRO-embedded TSX: AIAI | OTCQB: AINMF | FRA: PF0 CORPORATE PRESENTATION | JUNE 2026
Slide 2: Disclaimer
CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement in DISCLAIMER this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, including statements reg
Slide 3: Risk Factors
RISK FACTORS RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The ris ks and uncertainties desc ribed herein are not the only ones the Company faces. Additional risks and uncertainties,
Slide 4: The Problem
4 The Problem Pharma Companies Collect Massive Trial Data — But Often Miss the Signals That Matter Up to 65% of late-stage trials fail driven by enrolling the wrong patient population THE DATA HOLDS THE ANSWER — BUT TRADITIONAL METHODS CAN'T FIND IT Traditional analyses average across the entire pop
Slide 5: The Solution — NetraAI
5 The Solution — NetraAI Explainable AI That Finds Who Is Driving the Signal NetraAI EXPLAINABLE STRATIFICATION SPONSOR ANALYSIS SUBGROUPS STRATEGY DATA Phase 1–3 trial → Proprietary AI → 2–4 key variables → Protocol/SAP-ready identifies hidden define each criteria for next- datasets subpopulations
Slide 6: The Parallel for NetraAI
6 The Parallel for NetraAI Like finding the hidden information in a stereogram
Slide 7: Proven Results
7 Proven Results From Failed Signals to Precision Treatment Effects What NetraAI found: Two small, clinically interpretable changes to standard eligibility criteria — removal of subjects with (1) a Baseline Score of 0 on HAMD SS GI, and (2) Systolic BP of 137–143 — transformed a failed trial signal
Slide 8: Scientific Foundation
8 Scientific Foundation Peer-Reviewed, Publication-Backed CORE COLLABORATIONS 2025 / 2026 NIMH / MAYO / FMP Europe / CAMH npj DIGITAL MEDICINE (NATURE PORTFOLIO) Dec 2025 Peer-reviewed publication demonstrating explainable patient subpopulation discovery in clinical trial data. REGULATORY DEFENSIBIL
Slide 9: Competitive Moat
9 Competitive Moat Why This Cannot Be Easily Replicated FDA MEETING (CPIM) — NO OTHER AI HAS THIS We believe NetraAI is the only clinical trial AI platform to have undergone a closed-door FDA Critical Path Innovation Meeting. No traditional AI, ML, Bayesian, or standard statistical approach has achi
Slide 10: Total Addressable Market
10 Total Addressable Market ~34,500 Active Phase 2 & Phase 3 Trials Globally REVENUE OPPORTUNITY ~34,500 At C$300,000 average engagement price ~24,000 Phase 2: C$7.2B Phase 3: C$3.2B + ~10,500 = TOTAL: C$10.4 BILLION 1 ~34,500 trials × C$300K = C$10.4B Even capturing a fraction represents a transfor
Slide 11: Commercialization Strategy
11 Commercialization Strategy Two Routes to Market — Direct + Channel Partners DIRECT TO SPONSORS/CLIENTS CHANNEL PARTNERS ▸ Phase 2 readout analysis leading to Phase 3 trial ▸ Worldwide Clinical Trials (WCT): MSA executed, decisions quality assurance complete (Oct 2025) ▸ Phase 3 readout analysis l
Slide 12: Leadership Team
12 Leadership Team Proven Expertise Across AI, Pharma, Regulatory, and Capital Markets Dr. Angelico Carta
Slide 13: NetraMark Investment Highlights
13 NetraMark Investment Highlights FDA-reviewed and aligned AI platform — we believe we have the only clinical trial AI to complete an FDA CPIM High-margin, scalable services model — C$250 - C$350K per 6-week engagement; growing contract values Peer-reviewed validation in Nature portfolio — provides
Slide 14: Tale of the Tape
14 Tale of the Tape Capital Structure & Market Data Shares Outstanding 91.8 million 52-Week Range $0.68 – $1.10 Insider Ownership ~22 million shares (fully diluted) Listings TSX: AIAI | OTCQB: AINMF | FRA: PF0 Source: TMX Money. Market data as of last available. Subject to change.
Slide 15: Thank You
Thank You George Achilleos | CEO george@netramark.com netramark.com TSX: AIAI | OTCQB: AINMF | FRA: PF0
NetraMark Holdings — Investor Presentation (June 2026) on 6ix